Faron Pharmaceuticals Oy's () chief executive Dr Markku Jalkanen tells Proactive London's Andrew Scott its drug Traumakine has been admitted to a large-scale global programme that will assess its potential in treating severe pneumonia.
The study also includes patients suffering from the latest virus outbreak.
The interferon beta-1 formulation will be delivered intravenously, which he says offers the best “delivery route” for critically ill patients.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE